Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eribulin + Gemcitabine vs Paclitaxel + Gemcitabine in HER2- MBC
NCT02263495Phase 2Completed
- Sponsor
- Asan Medical Center
- Start
- Dec 2014
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of eribulin in breast cancer (2 arms), sponsored by Asan Medical Center. Primary endpoint: Progression-Free Survival at 48 months. Started Dec 2014; status: completed.
02
Drugs
eribulin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02263495.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02263495.